ImmunityBio Q2 FY26 net loss widens to $230.4 million; revenue rises 92% YoY to $50.7 million
IBRX•Quarterly results and operating expenses
- ImmunityBio posted Q2 net product revenue of $50.7 million, up 92% year-over-year and up 15% sequentially.
- Net loss attributable to common stockholders widened to $230.4 million; adjusted net loss (non-GAAP) narrowed to $81.0 million.
- R&D expense rose to $60.8 million; SG&A expense increased to $51.8 million.
- First-half net product revenue climbed to $94.8 million, up 121% versus the prior-year period.
- Cash, cash equivalents and marketable securities totaled $357.4 million; the FDA set a Jan. 6, 2027 PDUFA date for an ANKTIVA sBLA.
Related News
Aquestive reports positive human factors, PK results for Anaphylm epinephrine sublingual film in healthy volunteers
AQST•
Quantum Cyber sues White Diamond Research, Stocktwits for alleged market manipulation, seeks $5.69 million damages
QUCY•
